Showing 81-90 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Growing Beta Cell Replacement in T1D by Tolerizing Stem Cell-Derived Islets | Regents of the University of Minnesota | Bernhard Hering | Cures | 01-August-2025 to 31-July-2027 | $688.430,02 |
| Innovation Partnership | LabCentral | Luke Wallrich | Cures | 07-July-2025 to 31-May-2026 | $200.000,00 |
| Enhancing Functional Maturation of Stem Cell-Derived Beta Cells Using Harmine for Improved Diabetes Therapy | Icahn School of Medicine at Mount Sinai | Peng Wang | Cures | 01-July-2025 to 30-June-2026 | $305.000,00 |
| ST2 Tregs in enhancing islet transplantation | Rector & Visitors of the University of Virginia | Rahul Sharma | Cures | 01-July-2025 to 30-June-2028 | $499.997,13 |
| SOLUBLE LYMPHOCYTE ACTIVATION GENE-3 (s-LAG-3): A POTENTIAL SURROGATE MARKER FOR TYPE-1 DIABETES PROGRESSION AND IMMUNOTHERAPY SUCCESS | Trustees of Indiana University | Jon Piganelli | Cures | 01-July-2025 to 30-June-2026 | $153.000,00 |
| Evaluating gene-modified hypo-immune PSCs for immune evasion in NHPs | Trustees of the University of Pennsylvania | Ji Lei | Cures | 01-June-2025 to 31-May-2027 | $749.999,08 |
| Evaluating the Effectiveness and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 1 Diabetes | Emory University | Hui Shao | Improving Lives | 01-July-2025 to 30-June-2027 | $599.998,91 |
| Anti-Serpin B13 Hu-mAb Lead Candidate Developability Assessment | Mosaic Biosciences, Inc. | Malavi Madireddi | Cures | 01-June-2025 to 22-July-2026 | $293.674,00 |
| Development of an AI-informed Bayesian decision support system for optimizing benefit in islet transplant therapy | Oregon State University | Peter Jacobs | Cures | 01-June-2025 to 31-May-2028 | $749.999,83 |
| Unraveling the Influence of Obesity on Progression Along Preclinical Stages of Type 1 Diabetes | Baylor College of Medicine | Maria Redondo | Cures | 01-June-2025 to 31-May-2028 | $1.124.188,00 |